User:Chantestuser/sandbox/ArthurBrown

Arthur M. “Buzz” Brown, M.D., Ph.D. is ChanTest’s founder, Executive Chairman & CSO, and an Adjunct Professor of Physiology and Biophysics at Case Western Reserve University, School of Medicine.

He is a trained cardiologist and physiologist with more than 30 years of experience in ion channels and their relationship to human disease and has published extensively in peer-reviewed journals.

Dr. Brown has established world-leading Physiology department at University of Texas Medical Branch, Baylor College of Medicine and Case Western Reserve University.

ChanTest
ChanTest company information needed here

ChanRX
ChanRX company information needed here

Honors and contributions
Dr. Brown’s honors include the following:
 * Recipient of the prestigious Distinguished Service Award by the Safety Pharmacology Society (SPS) in 2013
 * Established Investigator of the American Heart Association
 * Javits Neuroscience Investigator Award
 * The Harry B van Dyke Awards for Excellence in Medical Research (Pharmacology), Columbia University College of Physicians and Surgeons
 * American Physiological Society Water B. Cannon Lecturer
 * Recipient of American Heart Association Basic Research Prize
 * Recipient of Louis and Artur Lucian Award for Research in Circulatory Diseases
 * First Robert M. Berne Distinguished Lecturer of the American Physiological Society Cardiovascular Section
 * Newton-Abraham Visiting Professor in Medical, Biological and Chemical Sciences, (MA Honors), University of Oxford, England

Major contributions from his research laboratories to the field of ion channels include: Dr. Brown is currently a collaborator with the US Federal Drug Administration (FDA) on cardiac safety issues. He holds nine patents on ion channel pharmacology, therapeutics and devices.
 * Invention of ion-selective liquid exchanger microelectrodes ;
 * Description of membrane–delimited G protein effects on ion channels ;
 * Identification of the pore of voltage-gated and inwardly rectifying potassium channels ;
 * Specification of hERG potassium channel as lethal target for non-cardiac drugs, e.g., Seldane, Propulsid, etc.
 * Discovery of drug-induced block of hERG trafficking as cause of arrhythmias.